West Pharma (WST) Tops Q3 EPS by 35c, provides guidance

West Pharma (NYSE: WST) reported Q3 EPS of $1.85, $0.35 better than the analyst estimate of $1.50. Revenue for the quarter came in at $746.9 million versus the consensus estimate of $709.3 million.

GUIDANCE:

West Pharma sees FY2024 EPS of $6.55-$6.75, versus the consensus of $6.41. West Pharma sees FY2024 revenue of $2.875-2.905 billion, versus the consensus of $2.874 billion.

For earnings history and earnings-related data on West Pharma (WST) click here.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• Boeing wins $13.4 billion contract modification from US military
• RH (RH) Tops Q2 EPS by $2.31